nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—Methotrexate—psoriasis	0.0937	0.132	CbGbCtD
Raloxifene—CYP19A1—Betamethasone—psoriasis	0.0934	0.131	CbGbCtD
Raloxifene—CYP2C8—Tazarotene—psoriasis	0.0918	0.129	CbGbCtD
Raloxifene—CYP19A1—Dexamethasone—psoriasis	0.0543	0.0763	CbGbCtD
Raloxifene—CYP2B6—Cholecalciferol—psoriasis	0.0518	0.0727	CbGbCtD
Raloxifene—CYP2C8—Cholecalciferol—psoriasis	0.0392	0.0551	CbGbCtD
Raloxifene—CYP2C8—Mycophenolate mofetil—psoriasis	0.034	0.0477	CbGbCtD
Raloxifene—CYP3A4—Calcitriol—psoriasis	0.0309	0.0434	CbGbCtD
Raloxifene—CYP2C8—Hydrocortisone—psoriasis	0.0273	0.0383	CbGbCtD
Raloxifene—CYP2C8—Cyclosporine—psoriasis	0.0258	0.0362	CbGbCtD
Raloxifene—CYP3A4—Methoxsalen—psoriasis	0.024	0.0337	CbGbCtD
Raloxifene—CYP2B6—Dexamethasone—psoriasis	0.0224	0.0315	CbGbCtD
Raloxifene—CYP2C8—Dexamethasone—psoriasis	0.017	0.0238	CbGbCtD
Raloxifene—CYP3A4—Cholecalciferol—psoriasis	0.0159	0.0223	CbGbCtD
Raloxifene—CYP3A4—Mycophenolate mofetil—psoriasis	0.0138	0.0194	CbGbCtD
Raloxifene—CYP3A4—Triamcinolone—psoriasis	0.0138	0.0194	CbGbCtD
Raloxifene—CYP3A4—Betamethasone—psoriasis	0.0118	0.0166	CbGbCtD
Raloxifene—CYP3A4—Prednisolone—psoriasis	0.0117	0.0164	CbGbCtD
Raloxifene—CYP3A4—Hydrocortisone—psoriasis	0.0111	0.0155	CbGbCtD
Raloxifene—CYP3A4—Prednisone—psoriasis	0.011	0.0155	CbGbCtD
Raloxifene—CYP3A4—Cyclosporine—psoriasis	0.0104	0.0147	CbGbCtD
Raloxifene—CYP3A4—Dexamethasone—psoriasis	0.00688	0.00966	CbGbCtD
Raloxifene—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.0013	1	CbGdCrCtD
Raloxifene—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000625	0.0132	CbGpPWpGaD
Raloxifene—ESR2—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000582	0.0123	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—TGFA—psoriasis	0.000574	0.0121	CbGpPWpGaD
Raloxifene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000536	0.0113	CbGpPWpGaD
Raloxifene—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000529	0.0112	CbGpPWpGaD
Raloxifene—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000514	0.0108	CbGpPWpGaD
Raloxifene—ESR2—Nuclear Receptors—PPARG—psoriasis	0.000513	0.0108	CbGpPWpGaD
Raloxifene—CYP19A1—Ovarian Infertility Genes—VDR—psoriasis	0.000476	0.01	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000468	0.00988	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.00044	0.0093	CbGpPWpGaD
Raloxifene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000435	0.00918	CbGpPWpGaD
Raloxifene—ESR1—Estrogen Receptor Pathway—JUN—psoriasis	0.000433	0.00914	CbGpPWpGaD
Raloxifene—ESR2—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000431	0.00909	CbGpPWpGaD
Raloxifene—CYP19A1—Biological oxidations—CYP2S1—psoriasis	0.000425	0.00897	CbGpPWpGaD
Raloxifene—CYP19A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000419	0.00884	CbGpPWpGaD
Raloxifene—ESR2—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000406	0.00856	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000399	0.00842	CbGpPWpGaD
Raloxifene—ESR1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000374	0.0079	CbGpPWpGaD
Raloxifene—ESR1—Nuclear Receptors—VDR—psoriasis	0.000371	0.00783	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—IL13—psoriasis	0.00037	0.0078	CbGpPWpGaD
Raloxifene—CYP19A1—Tryptophan metabolism—CAT—psoriasis	0.000367	0.00774	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—REL—psoriasis	0.000366	0.00773	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000357	0.00754	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000343	0.00723	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00032	0.00675	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000313	0.0066	CbGpPWpGaD
Raloxifene—EBP—Metabolism—NDUFA5—psoriasis	0.000298	0.00629	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000296	0.00624	CbGpPWpGaD
Raloxifene—ESR1—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000293	0.00619	CbGpPWpGaD
Raloxifene—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000291	0.00614	CbGpPWpGaD
Raloxifene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000288	0.00608	CbGpPWpGaD
Raloxifene—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000284	0.006	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000278	0.00587	CbGpPWpGaD
Raloxifene—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000276	0.00115	CcSEcCtD
Raloxifene—ESR1—Estrogen signaling pathway—JUN—psoriasis	0.000274	0.00579	CbGpPWpGaD
Raloxifene—Insomnia—Mycophenolic acid—psoriasis	0.000274	0.00114	CcSEcCtD
Raloxifene—Nausea—Acitretin—psoriasis	0.000273	0.00114	CcSEcCtD
Raloxifene—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000273	0.00576	CbGpPWpGaD
Raloxifene—Nausea—Fluocinolone Acetonide—psoriasis	0.000273	0.00114	CcSEcCtD
Raloxifene—Vertigo—Cyclosporine—psoriasis	0.00027	0.00113	CcSEcCtD
Raloxifene—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000269	0.00568	CbGpPWpGaD
Raloxifene—Dyspepsia—Mycophenolic acid—psoriasis	0.000266	0.00111	CcSEcCtD
Raloxifene—ESR1—Estrogen signaling pathway—NFKB1—psoriasis	0.000264	0.00557	CbGpPWpGaD
Raloxifene—Vertigo—Mycophenolate mofetil—psoriasis	0.000263	0.0011	CcSEcCtD
Raloxifene—Syncope—Mycophenolate mofetil—psoriasis	0.000262	0.0011	CcSEcCtD
Raloxifene—Cough—Cyclosporine—psoriasis	0.000262	0.00109	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000261	0.00109	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—HCAR2—psoriasis	0.000261	0.00551	CbGpPWpGaD
Raloxifene—Weight increased—Prednisone—psoriasis	0.000259	0.00108	CcSEcCtD
Raloxifene—Pain—Mycophenolic acid—psoriasis	0.000259	0.00108	CcSEcCtD
Raloxifene—ESR1—Nuclear Receptors—PPARG—psoriasis	0.000259	0.00546	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—TARS—psoriasis	0.000257	0.00543	CbGpPWpGaD
Raloxifene—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000257	0.00107	CcSEcCtD
Raloxifene—Myalgia—Cyclosporine—psoriasis	0.000255	0.00107	CcSEcCtD
Raloxifene—Chest pain—Cyclosporine—psoriasis	0.000255	0.00107	CcSEcCtD
Raloxifene—Arthralgia—Cyclosporine—psoriasis	0.000255	0.00107	CcSEcCtD
Raloxifene—Cough—Mycophenolate mofetil—psoriasis	0.000255	0.00107	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000254	0.00106	CcSEcCtD
Raloxifene—EBP—Metabolism—CYP2S1—psoriasis	0.000254	0.00535	CbGpPWpGaD
Raloxifene—Depression—Prednisone—psoriasis	0.000253	0.00106	CcSEcCtD
Raloxifene—Chest pain—Mycophenolate mofetil—psoriasis	0.000249	0.00104	CcSEcCtD
Raloxifene—Arthralgia—Mycophenolate mofetil—psoriasis	0.000249	0.00104	CcSEcCtD
Raloxifene—Myalgia—Mycophenolate mofetil—psoriasis	0.000249	0.00104	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—psoriasis	0.000249	0.00104	CcSEcCtD
Raloxifene—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000247	0.00103	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000247	0.00103	CcSEcCtD
Raloxifene—Diarrhoea—Hydroxyurea—psoriasis	0.000247	0.00103	CcSEcCtD
Raloxifene—Vertigo—Prednisolone—psoriasis	0.000245	0.00102	CcSEcCtD
Raloxifene—Syncope—Prednisolone—psoriasis	0.000245	0.00102	CcSEcCtD
Raloxifene—Infection—Cyclosporine—psoriasis	0.000243	0.00102	CcSEcCtD
Raloxifene—Nervous system disorder—Cyclosporine—psoriasis	0.00024	0.001	CcSEcCtD
Raloxifene—Loss of consciousness—Prednisolone—psoriasis	0.00024	0.001	CcSEcCtD
Raloxifene—ESR2—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.00024	0.00506	CbGpPWpGaD
Raloxifene—Thrombocytopenia—Cyclosporine—psoriasis	0.00024	0.001	CcSEcCtD
Raloxifene—Vertigo—Hydrocortisone—psoriasis	0.00024	0.001	CcSEcCtD
Raloxifene—Abdominal pain—Mycophenolic acid—psoriasis	0.000239	0.000999	CcSEcCtD
Raloxifene—Body temperature increased—Mycophenolic acid—psoriasis	0.000239	0.000999	CcSEcCtD
Raloxifene—Syncope—Hydrocortisone—psoriasis	0.000239	0.000998	CcSEcCtD
Raloxifene—Dizziness—Hydroxyurea—psoriasis	0.000239	0.000998	CcSEcCtD
Raloxifene—HTR2B—GPCR ligand binding—HCAR2—psoriasis	0.000238	0.00503	CbGpPWpGaD
Raloxifene—Skin disorder—Cyclosporine—psoriasis	0.000238	0.000993	CcSEcCtD
Raloxifene—Angiopathy—Betamethasone—psoriasis	0.000237	0.000991	CcSEcCtD
Raloxifene—Angiopathy—Dexamethasone—psoriasis	0.000237	0.000991	CcSEcCtD
Raloxifene—Infection—Mycophenolate mofetil—psoriasis	0.000237	0.000991	CcSEcCtD
Raloxifene—Hyperhidrosis—Cyclosporine—psoriasis	0.000237	0.000988	CcSEcCtD
Raloxifene—Shock—Mycophenolate mofetil—psoriasis	0.000235	0.000981	CcSEcCtD
Raloxifene—Loss of consciousness—Hydrocortisone—psoriasis	0.000234	0.000978	CcSEcCtD
Raloxifene—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000234	0.000978	CcSEcCtD
Raloxifene—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000234	0.000976	CcSEcCtD
Raloxifene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000233	0.00493	CbGpPWpGaD
Raloxifene—Skin disorder—Mycophenolate mofetil—psoriasis	0.000232	0.000969	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000231	0.00488	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000231	0.00487	CbGpPWpGaD
Raloxifene—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000231	0.000964	CcSEcCtD
Raloxifene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00023	0.00486	CbGpPWpGaD
Raloxifene—Vomiting—Hydroxyurea—psoriasis	0.00023	0.000959	CcSEcCtD
Raloxifene—Rash—Hydroxyurea—psoriasis	0.000228	0.000951	CcSEcCtD
Raloxifene—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000228	0.00481	CbGpPWpGaD
Raloxifene—Dermatitis—Hydroxyurea—psoriasis	0.000228	0.00095	CcSEcCtD
Raloxifene—Myalgia—Hydrocortisone—psoriasis	0.000227	0.000948	CcSEcCtD
Raloxifene—Headache—Hydroxyurea—psoriasis	0.000226	0.000945	CcSEcCtD
Raloxifene—Vertigo—Triamcinolone—psoriasis	0.000226	0.000942	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000225	0.000941	CcSEcCtD
Raloxifene—Syncope—Triamcinolone—psoriasis	0.000225	0.00094	CcSEcCtD
Raloxifene—Connective tissue disorder—Prednisone—psoriasis	0.000224	0.000935	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000223	0.000931	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000222	0.00469	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—IL10—psoriasis	0.000221	0.00467	CbGpPWpGaD
Raloxifene—Insomnia—Cyclosporine—psoriasis	0.000221	0.000925	CcSEcCtD
Raloxifene—Loss of consciousness—Triamcinolone—psoriasis	0.000221	0.000921	CcSEcCtD
Raloxifene—Shock—Prednisolone—psoriasis	0.000219	0.000915	CcSEcCtD
Raloxifene—Cough—Triamcinolone—psoriasis	0.000219	0.000915	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000218	0.000909	CcSEcCtD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000217	0.00458	CbGpPWpGaD
Raloxifene—Infection—Hydrocortisone—psoriasis	0.000216	0.000903	CcSEcCtD
Raloxifene—Insomnia—Mycophenolate mofetil—psoriasis	0.000216	0.000902	CcSEcCtD
Raloxifene—Dyspepsia—Cyclosporine—psoriasis	0.000216	0.0009	CcSEcCtD
Raloxifene—ESR1—AP-1 transcription factor network—IL4—psoriasis	0.000215	0.00455	CbGpPWpGaD
Raloxifene—Hyperhidrosis—Prednisolone—psoriasis	0.000215	0.000899	CcSEcCtD
Raloxifene—Nausea—Hydroxyurea—psoriasis	0.000215	0.000896	CcSEcCtD
Raloxifene—Shock—Hydrocortisone—psoriasis	0.000214	0.000894	CcSEcCtD
Raloxifene—Myalgia—Triamcinolone—psoriasis	0.000214	0.000892	CcSEcCtD
Raloxifene—Nervous system disorder—Hydrocortisone—psoriasis	0.000213	0.000891	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—psoriasis	0.000213	0.000891	CcSEcCtD
Raloxifene—Depression—Methotrexate—psoriasis	0.000212	0.000883	CcSEcCtD
Raloxifene—Flushing—Prednisone—psoriasis	0.000211	0.000883	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000211	0.000883	CcSEcCtD
Raloxifene—Skin disorder—Hydrocortisone—psoriasis	0.000211	0.000882	CcSEcCtD
Raloxifene—Hyperhidrosis—Hydrocortisone—psoriasis	0.00021	0.000878	CcSEcCtD
Raloxifene—Dyspepsia—Mycophenolate mofetil—psoriasis	0.00021	0.000878	CcSEcCtD
Raloxifene—Pain—Cyclosporine—psoriasis	0.000209	0.000874	CcSEcCtD
Raloxifene—Diarrhoea—Mycophenolic acid—psoriasis	0.000207	0.000865	CcSEcCtD
Raloxifene—Angiopathy—Prednisone—psoriasis	0.000207	0.000863	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—psoriasis	0.000206	0.000861	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000206	0.000861	CcSEcCtD
Raloxifene—Vertigo—Betamethasone—psoriasis	0.000205	0.000854	CcSEcCtD
Raloxifene—Vertigo—Dexamethasone—psoriasis	0.000205	0.000854	CcSEcCtD
Raloxifene—ESR1—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000204	0.00432	CbGpPWpGaD
Raloxifene—Syncope—Betamethasone—psoriasis	0.000204	0.000853	CcSEcCtD
Raloxifene—Syncope—Dexamethasone—psoriasis	0.000204	0.000853	CcSEcCtD
Raloxifene—Pain—Mycophenolate mofetil—psoriasis	0.000204	0.000853	CcSEcCtD
Raloxifene—Infection—Triamcinolone—psoriasis	0.000204	0.00085	CcSEcCtD
Raloxifene—Sweating—Methotrexate—psoriasis	0.000203	0.000849	CcSEcCtD
Raloxifene—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000203	0.00428	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000203	0.00428	CbGpPWpGaD
Raloxifene—Shock—Triamcinolone—psoriasis	0.000202	0.000842	CcSEcCtD
Raloxifene—Insomnia—Prednisolone—psoriasis	0.000202	0.000841	CcSEcCtD
Raloxifene—Gastrointestinal pain—Cyclosporine—psoriasis	0.0002	0.000836	CcSEcCtD
Raloxifene—Loss of consciousness—Dexamethasone—psoriasis	0.0002	0.000836	CcSEcCtD
Raloxifene—Loss of consciousness—Betamethasone—psoriasis	0.0002	0.000836	CcSEcCtD
Raloxifene—Dizziness—Mycophenolic acid—psoriasis	0.0002	0.000836	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000198	0.000828	CcSEcCtD
Raloxifene—Hyperhidrosis—Triamcinolone—psoriasis	0.000198	0.000827	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000197	0.00416	CbGpPWpGaD
Raloxifene—Insomnia—Hydrocortisone—psoriasis	0.000197	0.000822	CcSEcCtD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000196	0.00414	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000195	0.000815	CcSEcCtD
Raloxifene—ESR1—AP-1 transcription factor network—HLA-A—psoriasis	0.000195	0.00412	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—NOS2—psoriasis	0.000195	0.00411	CbGpPWpGaD
Raloxifene—Myalgia—Dexamethasone—psoriasis	0.000194	0.00081	CcSEcCtD
Raloxifene—Myalgia—Betamethasone—psoriasis	0.000194	0.00081	CcSEcCtD
Raloxifene—Body temperature increased—Cyclosporine—psoriasis	0.000194	0.000808	CcSEcCtD
Raloxifene—Abdominal pain—Cyclosporine—psoriasis	0.000194	0.000808	CcSEcCtD
Raloxifene—Vomiting—Mycophenolic acid—psoriasis	0.000192	0.000803	CcSEcCtD
Raloxifene—Dyspepsia—Hydrocortisone—psoriasis	0.000192	0.0008	CcSEcCtD
Raloxifene—Rash—Mycophenolic acid—psoriasis	0.000191	0.000797	CcSEcCtD
Raloxifene—Dermatitis—Mycophenolic acid—psoriasis	0.000191	0.000796	CcSEcCtD
Raloxifene—Pain—Prednisolone—psoriasis	0.000191	0.000795	CcSEcCtD
Raloxifene—Headache—Mycophenolic acid—psoriasis	0.00019	0.000792	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—psoriasis	0.000189	0.000789	CcSEcCtD
Raloxifene—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000189	0.000788	CcSEcCtD
Raloxifene—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000189	0.000788	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—psoriasis	0.000188	0.000785	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000188	0.000784	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—psoriasis	0.000187	0.000779	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000187	0.000779	CcSEcCtD
Raloxifene—Pain—Hydrocortisone—psoriasis	0.000186	0.000777	CcSEcCtD
Raloxifene—Insomnia—Triamcinolone—psoriasis	0.000185	0.000774	CcSEcCtD
Raloxifene—Infection—Dexamethasone—psoriasis	0.000185	0.000771	CcSEcCtD
Raloxifene—Infection—Betamethasone—psoriasis	0.000185	0.000771	CcSEcCtD
Raloxifene—Shock—Betamethasone—psoriasis	0.000183	0.000764	CcSEcCtD
Raloxifene—Shock—Dexamethasone—psoriasis	0.000183	0.000764	CcSEcCtD
Raloxifene—Nervous system disorder—Betamethasone—psoriasis	0.000182	0.000761	CcSEcCtD
Raloxifene—Nervous system disorder—Dexamethasone—psoriasis	0.000182	0.000761	CcSEcCtD
Raloxifene—Thrombocytopenia—Betamethasone—psoriasis	0.000182	0.00076	CcSEcCtD
Raloxifene—Thrombocytopenia—Dexamethasone—psoriasis	0.000182	0.00076	CcSEcCtD
Raloxifene—Dyspepsia—Triamcinolone—psoriasis	0.00018	0.000753	CcSEcCtD
Raloxifene—Nausea—Mycophenolic acid—psoriasis	0.00018	0.000751	CcSEcCtD
Raloxifene—Hyperhidrosis—Dexamethasone—psoriasis	0.00018	0.00075	CcSEcCtD
Raloxifene—Hyperhidrosis—Betamethasone—psoriasis	0.00018	0.00075	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.00018	0.00379	CbGpPWpGaD
Raloxifene—Vertigo—Prednisone—psoriasis	0.000178	0.000744	CcSEcCtD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000178	0.00376	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000178	0.000743	CcSEcCtD
Raloxifene—Syncope—Prednisone—psoriasis	0.000178	0.000743	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—psoriasis	0.000177	0.000738	CcSEcCtD
Raloxifene—Pain—Triamcinolone—psoriasis	0.000175	0.000732	CcSEcCtD
Raloxifene—Loss of consciousness—Prednisone—psoriasis	0.000174	0.000728	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—psoriasis	0.000173	0.000721	CcSEcCtD
Raloxifene—ESR1—Leptin signaling pathway—LEP—psoriasis	0.000172	0.00364	CbGpPWpGaD
Raloxifene—Abdominal pain—Hydrocortisone—psoriasis	0.000172	0.000718	CcSEcCtD
Raloxifene—Body temperature increased—Hydrocortisone—psoriasis	0.000172	0.000718	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000169	0.000707	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000169	0.000707	CcSEcCtD
Raloxifene—Myalgia—Prednisone—psoriasis	0.000169	0.000705	CcSEcCtD
Raloxifene—Arthralgia—Prednisone—psoriasis	0.000169	0.000705	CcSEcCtD
Raloxifene—ESR2—Generic Transcription Pathway—CARM1—psoriasis	0.000168	0.00355	CbGpPWpGaD
Raloxifene—Insomnia—Dexamethasone—psoriasis	0.000168	0.000702	CcSEcCtD
Raloxifene—Insomnia—Betamethasone—psoriasis	0.000168	0.000702	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000168	0.0007	CcSEcCtD
Raloxifene—Diarrhoea—Cyclosporine—psoriasis	0.000168	0.000699	CcSEcCtD
Raloxifene—AOX1—Metabolism—NDUFA5—psoriasis	0.000165	0.00349	CbGpPWpGaD
Raloxifene—Dyspepsia—Dexamethasone—psoriasis	0.000164	0.000683	CcSEcCtD
Raloxifene—Dyspepsia—Betamethasone—psoriasis	0.000164	0.000683	CcSEcCtD
Raloxifene—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000163	0.000682	CcSEcCtD
Raloxifene—ESR1—FOXA1 transcription factor network—JUN—psoriasis	0.000163	0.00344	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000162	0.00343	CbGpPWpGaD
Raloxifene—Body temperature increased—Triamcinolone—psoriasis	0.000162	0.000676	CcSEcCtD
Raloxifene—Dizziness—Cyclosporine—psoriasis	0.000162	0.000676	CcSEcCtD
Raloxifene—Infection—Prednisone—psoriasis	0.000161	0.000672	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00016	0.00067	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Betamethasone—psoriasis	0.00016	0.00067	CcSEcCtD
Raloxifene—Shock—Prednisone—psoriasis	0.000159	0.000665	CcSEcCtD
Raloxifene—Pain—Betamethasone—psoriasis	0.000159	0.000664	CcSEcCtD
Raloxifene—Pain—Dexamethasone—psoriasis	0.000159	0.000664	CcSEcCtD
Raloxifene—Nervous system disorder—Prednisone—psoriasis	0.000159	0.000663	CcSEcCtD
Raloxifene—Dizziness—Mycophenolate mofetil—psoriasis	0.000158	0.000659	CcSEcCtD
Raloxifene—Skin disorder—Prednisone—psoriasis	0.000157	0.000657	CcSEcCtD
Raloxifene—Hyperhidrosis—Prednisone—psoriasis	0.000157	0.000653	CcSEcCtD
Raloxifene—Vomiting—Cyclosporine—psoriasis	0.000156	0.00065	CcSEcCtD
Raloxifene—Rash—Cyclosporine—psoriasis	0.000154	0.000645	CcSEcCtD
Raloxifene—Dermatitis—Cyclosporine—psoriasis	0.000154	0.000644	CcSEcCtD
Raloxifene—Headache—Cyclosporine—psoriasis	0.000153	0.00064	CcSEcCtD
Raloxifene—Gastrointestinal pain—Betamethasone—psoriasis	0.000152	0.000635	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dexamethasone—psoriasis	0.000152	0.000635	CcSEcCtD
Raloxifene—Vomiting—Mycophenolate mofetil—psoriasis	0.000152	0.000634	CcSEcCtD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000152	0.0032	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000151	0.00318	CbGpPWpGaD
Raloxifene—Rash—Mycophenolate mofetil—psoriasis	0.000151	0.000629	CcSEcCtD
Raloxifene—Dermatitis—Mycophenolate mofetil—psoriasis	0.00015	0.000628	CcSEcCtD
Raloxifene—Headache—Mycophenolate mofetil—psoriasis	0.00015	0.000625	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—IFNG—psoriasis	0.000149	0.00315	CbGpPWpGaD
Raloxifene—Vertigo—Methotrexate—psoriasis	0.000149	0.000622	CcSEcCtD
Raloxifene—Diarrhoea—Hydrocortisone—psoriasis	0.000149	0.000622	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Prednisone—psoriasis	0.000147	0.000616	CcSEcCtD
Raloxifene—HTR6—GPCR downstream signaling—HCAR2—psoriasis	0.000147	0.00311	CbGpPWpGaD
Raloxifene—Dizziness—Prednisolone—psoriasis	0.000147	0.000615	CcSEcCtD
Raloxifene—Body temperature increased—Dexamethasone—psoriasis	0.000147	0.000614	CcSEcCtD
Raloxifene—Body temperature increased—Betamethasone—psoriasis	0.000147	0.000614	CcSEcCtD
Raloxifene—Abdominal pain—Dexamethasone—psoriasis	0.000147	0.000614	CcSEcCtD
Raloxifene—Abdominal pain—Betamethasone—psoriasis	0.000147	0.000614	CcSEcCtD
Raloxifene—Insomnia—Prednisone—psoriasis	0.000146	0.000611	CcSEcCtD
Raloxifene—Nausea—Cyclosporine—psoriasis	0.000145	0.000607	CcSEcCtD
Raloxifene—Cough—Methotrexate—psoriasis	0.000145	0.000604	CcSEcCtD
Raloxifene—Dizziness—Hydrocortisone—psoriasis	0.000144	0.000601	CcSEcCtD
Raloxifene—Dyspepsia—Prednisone—psoriasis	0.000143	0.000595	CcSEcCtD
Raloxifene—Nausea—Mycophenolate mofetil—psoriasis	0.000142	0.000592	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—psoriasis	0.000141	0.000589	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—psoriasis	0.000141	0.000589	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—psoriasis	0.000141	0.000589	CcSEcCtD
Raloxifene—AOX1—Metabolism—CYP2S1—psoriasis	0.00014	0.00296	CbGpPWpGaD
Raloxifene—Rash—Prednisolone—psoriasis	0.00014	0.000587	CcSEcCtD
Raloxifene—Dermatitis—Prednisolone—psoriasis	0.00014	0.000586	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00014	0.000585	CcSEcCtD
Raloxifene—Headache—Prednisolone—psoriasis	0.00014	0.000583	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—CXCL8—psoriasis	0.000139	0.00293	CbGpPWpGaD
Raloxifene—Vomiting—Hydrocortisone—psoriasis	0.000138	0.000578	CcSEcCtD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000138	0.0029	CbGpPWpGaD
Raloxifene—Rash—Hydrocortisone—psoriasis	0.000137	0.000573	CcSEcCtD
Raloxifene—Dermatitis—Hydrocortisone—psoriasis	0.000137	0.000572	CcSEcCtD
Raloxifene—Headache—Hydrocortisone—psoriasis	0.000136	0.000569	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—CCL20—psoriasis	0.000136	0.00286	CbGpPWpGaD
Raloxifene—Dizziness—Triamcinolone—psoriasis	0.000135	0.000566	CcSEcCtD
Raloxifene—HTR2B—GPCR downstream signaling—HCAR2—psoriasis	0.000135	0.00284	CbGpPWpGaD
Raloxifene—Infection—Methotrexate—psoriasis	0.000134	0.000561	CcSEcCtD
Raloxifene—HTR6—Signaling by GPCR—HCAR2—psoriasis	0.000134	0.00283	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—IFNG—psoriasis	0.000133	0.00281	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000133	0.0028	CbGpPWpGaD
Raloxifene—Nervous system disorder—Methotrexate—psoriasis	0.000133	0.000554	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—psoriasis	0.000132	0.000553	CcSEcCtD
Raloxifene—Gastrointestinal pain—Prednisone—psoriasis	0.000132	0.000553	CcSEcCtD
Raloxifene—Nausea—Prednisolone—psoriasis	0.000132	0.000553	CcSEcCtD
Raloxifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000132	0.00279	CbGpPWpGaD
Raloxifene—Skin disorder—Methotrexate—psoriasis	0.000131	0.000549	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—psoriasis	0.000131	0.000546	CcSEcCtD
Raloxifene—Vomiting—Triamcinolone—psoriasis	0.00013	0.000544	CcSEcCtD
Raloxifene—ESR1—AP-1 transcription factor network—IFNG—psoriasis	0.00013	0.00275	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—TARS—psoriasis	0.00013	0.00274	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000129	0.00273	CbGpPWpGaD
Raloxifene—Nausea—Hydrocortisone—psoriasis	0.000129	0.00054	CcSEcCtD
Raloxifene—Rash—Triamcinolone—psoriasis	0.000129	0.000539	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—JUN—psoriasis	0.000129	0.00272	CbGpPWpGaD
Raloxifene—Dermatitis—Triamcinolone—psoriasis	0.000129	0.000539	CcSEcCtD
Raloxifene—Headache—Triamcinolone—psoriasis	0.000128	0.000536	CcSEcCtD
Raloxifene—Abdominal pain—Prednisone—psoriasis	0.000128	0.000534	CcSEcCtD
Raloxifene—Body temperature increased—Prednisone—psoriasis	0.000128	0.000534	CcSEcCtD
Raloxifene—Diarrhoea—Dexamethasone—psoriasis	0.000127	0.000531	CcSEcCtD
Raloxifene—Diarrhoea—Betamethasone—psoriasis	0.000127	0.000531	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000126	0.00267	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000124	0.00262	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CARM1—psoriasis	0.000124	0.00261	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CCL20—psoriasis	0.000124	0.00261	CbGpPWpGaD
Raloxifene—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000123	0.000515	CcSEcCtD
Raloxifene—Dizziness—Betamethasone—psoriasis	0.000123	0.000513	CcSEcCtD
Raloxifene—Dizziness—Dexamethasone—psoriasis	0.000123	0.000513	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—psoriasis	0.000122	0.000511	CcSEcCtD
Raloxifene—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000122	0.00258	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HCAR2—psoriasis	0.000122	0.00258	CbGpPWpGaD
Raloxifene—Nausea—Triamcinolone—psoriasis	0.000122	0.000508	CcSEcCtD
Raloxifene—ESR1—AP-1 transcription factor network—CXCL8—psoriasis	0.000121	0.00256	CbGpPWpGaD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.000121	0.00255	CbGpPWpGaD
Raloxifene—Dyspepsia—Methotrexate—psoriasis	0.000119	0.000497	CcSEcCtD
Raloxifene—Vomiting—Dexamethasone—psoriasis	0.000118	0.000494	CcSEcCtD
Raloxifene—Vomiting—Betamethasone—psoriasis	0.000118	0.000494	CcSEcCtD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000118	0.00249	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—JUN—psoriasis	0.000118	0.00248	CbGpPWpGaD
Raloxifene—Rash—Dexamethasone—psoriasis	0.000117	0.000489	CcSEcCtD
Raloxifene—Rash—Betamethasone—psoriasis	0.000117	0.000489	CcSEcCtD
Raloxifene—Dermatitis—Betamethasone—psoriasis	0.000117	0.000489	CcSEcCtD
Raloxifene—Dermatitis—Dexamethasone—psoriasis	0.000117	0.000489	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—psoriasis	0.000117	0.000488	CcSEcCtD
Raloxifene—Headache—Dexamethasone—psoriasis	0.000116	0.000486	CcSEcCtD
Raloxifene—Headache—Betamethasone—psoriasis	0.000116	0.000486	CcSEcCtD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000116	0.00244	CbGpPWpGaD
Raloxifene—Pain—Methotrexate—psoriasis	0.000116	0.000483	CcSEcCtD
Raloxifene—ESR1—Regulation of Telomerase—JUN—psoriasis	0.000115	0.00243	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000113	0.00239	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—JUN—psoriasis	0.000113	0.00238	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—NFKB1—psoriasis	0.000111	0.00234	CbGpPWpGaD
Raloxifene—Diarrhoea—Prednisone—psoriasis	0.000111	0.000462	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—psoriasis	0.000111	0.000462	CcSEcCtD
Raloxifene—Nausea—Dexamethasone—psoriasis	0.00011	0.000461	CcSEcCtD
Raloxifene—Nausea—Betamethasone—psoriasis	0.00011	0.000461	CcSEcCtD
Raloxifene—ESR1—LKB1 signaling events—TP53—psoriasis	0.00011	0.00232	CbGpPWpGaD
Raloxifene—Dizziness—Prednisone—psoriasis	0.000107	0.000447	CcSEcCtD
Raloxifene—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000107	0.00226	CbGpPWpGaD
Raloxifene—Abdominal pain—Methotrexate—psoriasis	0.000107	0.000447	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—psoriasis	0.000107	0.000447	CcSEcCtD
Raloxifene—Vomiting—Prednisone—psoriasis	0.000103	0.00043	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000103	0.00217	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—NFKB1—psoriasis	0.000103	0.00216	CbGpPWpGaD
Raloxifene—Rash—Prednisone—psoriasis	0.000102	0.000426	CcSEcCtD
Raloxifene—Dermatitis—Prednisone—psoriasis	0.000102	0.000426	CcSEcCtD
Raloxifene—Headache—Prednisone—psoriasis	0.000101	0.000423	CcSEcCtD
Raloxifene—ESR2—Generic Transcription Pathway—VDR—psoriasis	0.0001	0.00212	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.0001	0.00211	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.0001	0.00211	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	9.63e-05	0.00203	CbGpPWpGaD
Raloxifene—Nausea—Prednisone—psoriasis	9.62e-05	0.000402	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—psoriasis	9.26e-05	0.000387	CcSEcCtD
Raloxifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.22e-05	0.00195	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—STAT3—psoriasis	9.22e-05	0.00194	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.05e-05	0.00191	CbGpPWpGaD
Raloxifene—Dizziness—Methotrexate—psoriasis	8.95e-05	0.000374	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—TNF—psoriasis	8.8e-05	0.00186	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.74e-05	0.00184	CbGpPWpGaD
Raloxifene—Vomiting—Methotrexate—psoriasis	8.6e-05	0.000359	CcSEcCtD
Raloxifene—CYP19A1—Metabolism—NDUFA5—psoriasis	8.54e-05	0.0018	CbGpPWpGaD
Raloxifene—Rash—Methotrexate—psoriasis	8.53e-05	0.000356	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—psoriasis	8.52e-05	0.000356	CcSEcCtD
Raloxifene—ESR1—Generic Transcription Pathway—CARM1—psoriasis	8.48e-05	0.00179	CbGpPWpGaD
Raloxifene—Headache—Methotrexate—psoriasis	8.48e-05	0.000354	CcSEcCtD
Raloxifene—ESR2—Gene Expression—CARM1—psoriasis	8.1e-05	0.00171	CbGpPWpGaD
Raloxifene—Nausea—Methotrexate—psoriasis	8.04e-05	0.000336	CcSEcCtD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.97e-05	0.00168	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HCAR2—psoriasis	7.91e-05	0.00167	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—IL6—psoriasis	7.8e-05	0.00165	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CCL20—psoriasis	7.66e-05	0.00162	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CAT—psoriasis	7.62e-05	0.00161	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	7.61e-05	0.00161	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.49e-05	0.00158	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—TYK2—psoriasis	7.48e-05	0.00158	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—psoriasis	7.43e-05	0.00157	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP2S1—psoriasis	7.27e-05	0.00153	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HCAR2—psoriasis	7.22e-05	0.00152	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—IL6—psoriasis	7.11e-05	0.0015	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—PPARG—psoriasis	7e-05	0.00148	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CCL20—psoriasis	6.99e-05	0.00148	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CCL20—psoriasis	6.95e-05	0.00147	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CARM1—psoriasis	6.86e-05	0.00145	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TAGAP—psoriasis	6.86e-05	0.00145	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.8e-05	0.00144	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—IL6—psoriasis	6.8e-05	0.00144	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	6.8e-05	0.00143	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.6e-05	0.00139	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	6.54e-05	0.00138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CCL20—psoriasis	6.35e-05	0.00134	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TAGAP—psoriasis	6.26e-05	0.00132	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	6.09e-05	0.00128	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HCAR2—psoriasis	6.01e-05	0.00127	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	5.94e-05	0.00125	CbGpPWpGaD
Raloxifene—EBP—Metabolism—APOE—psoriasis	5.92e-05	0.00125	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	5.86e-05	0.00124	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NDUFA5—psoriasis	5.49e-05	0.00116	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	5.32e-05	0.00112	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TAGAP—psoriasis	5.21e-05	0.0011	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PPARG—psoriasis	5.15e-05	0.00109	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—VDR—psoriasis	5.07e-05	0.00107	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.04e-05	0.00106	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.85e-05	0.00102	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—VDR—psoriasis	4.84e-05	0.00102	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.81e-05	0.00101	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP2S1—psoriasis	4.67e-05	0.000985	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NDUFA5—psoriasis	4.65e-05	0.00098	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	4.49e-05	0.000947	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.41e-05	0.00093	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.39e-05	0.000926	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.33e-05	0.000914	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CAT—psoriasis	4.22e-05	0.000891	CbGpPWpGaD
Raloxifene—AOX1—Disease—HLA-A—psoriasis	4.19e-05	0.000885	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCL20—psoriasis	4.11e-05	0.000867	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—CARM1—psoriasis	4.08e-05	0.000862	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	4.02e-05	0.000848	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP2S1—psoriasis	3.95e-05	0.000834	CbGpPWpGaD
Raloxifene—AOX1—Disease—APOE—psoriasis	3.92e-05	0.000826	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.81e-05	0.000804	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.78e-05	0.000797	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCL20—psoriasis	3.75e-05	0.000791	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CXCL8—psoriasis	3.66e-05	0.000772	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—IL6—psoriasis	3.66e-05	0.000772	CbGpPWpGaD
Raloxifene—AOX1—Disease—NOS2—psoriasis	3.65e-05	0.00077	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CARM1—psoriasis	3.55e-05	0.000749	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—PPARG—psoriasis	3.53e-05	0.000745	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—PPARG—psoriasis	3.37e-05	0.000712	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CXCL8—psoriasis	3.34e-05	0.000705	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.33e-05	0.000703	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.33e-05	0.000702	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.32e-05	0.0007	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—APOE—psoriasis	3.28e-05	0.000692	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCL20—psoriasis	3.12e-05	0.000659	CbGpPWpGaD
Raloxifene—AOX1—Disease—TYK2—psoriasis	2.99e-05	0.000631	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PPARG—psoriasis	2.86e-05	0.000603	CbGpPWpGaD
Raloxifene—AOX1—Disease—CD4—psoriasis	2.7e-05	0.00057	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NDUFA5—psoriasis	2.49e-05	0.000526	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—VDR—psoriasis	2.44e-05	0.000515	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CARM1—psoriasis	2.28e-05	0.000481	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SOCS1—psoriasis	2.26e-05	0.000477	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CAT—psoriasis	2.18e-05	0.000461	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—TYK2—psoriasis	2.16e-05	0.000455	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2S1—psoriasis	2.12e-05	0.000447	CbGpPWpGaD
Raloxifene—AOX1—Disease—STAT3—psoriasis	2.09e-05	0.000442	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.07e-05	0.000437	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—psoriasis	2.07e-05	0.000436	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SOCS1—psoriasis	2.06e-05	0.000436	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—TYK2—psoriasis	1.97e-05	0.000415	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CARM1—psoriasis	1.93e-05	0.000407	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	1.89e-05	0.000398	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—psoriasis	1.88e-05	0.000396	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.8e-05	0.000381	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SOCS1—psoriasis	1.72e-05	0.000363	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—psoriasis	1.71e-05	0.000362	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—psoriasis	1.7e-05	0.000359	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—APOE—psoriasis	1.7e-05	0.000358	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—LEP—psoriasis	1.67e-05	0.000352	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOE—psoriasis	1.67e-05	0.000352	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NFKBIA—psoriasis	1.56e-05	0.000328	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—LEP—psoriasis	1.52e-05	0.000322	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOE—psoriasis	1.52e-05	0.000322	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—psoriasis	1.48e-05	0.000312	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—psoriasis	1.46e-05	0.000308	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKBIA—psoriasis	1.42e-05	0.0003	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CAT—psoriasis	1.4e-05	0.000296	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TYK2—psoriasis	1.27e-05	0.000269	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—LEP—psoriasis	1.27e-05	0.000268	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOE—psoriasis	1.27e-05	0.000268	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CAT—psoriasis	1.19e-05	0.00025	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKBIA—psoriasis	1.18e-05	0.00025	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TYK2—psoriasis	1.16e-05	0.000245	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—psoriasis	1.11e-05	0.000234	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOE—psoriasis	1.09e-05	0.00023	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—psoriasis	1.05e-05	0.000223	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CARM1—psoriasis	1.04e-05	0.000219	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUN—psoriasis	1.03e-05	0.000218	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—psoriasis	1.01e-05	0.000214	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NFKB1—psoriasis	9.93e-06	0.00021	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TYK2—psoriasis	9.69e-06	0.000204	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—psoriasis	9.63e-06	0.000203	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—psoriasis	9.49e-06	0.0002	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUN—psoriasis	9.41e-06	0.000199	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOE—psoriasis	9.22e-06	0.000195	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKB1—psoriasis	9.06e-06	0.000191	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—psoriasis	9.01e-06	0.00019	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—psoriasis	8.92e-06	0.000188	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—psoriasis	8.44e-06	0.000178	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—psoriasis	8.22e-06	0.000174	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—psoriasis	8.14e-06	0.000172	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—psoriasis	8.03e-06	0.000169	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUN—psoriasis	7.84e-06	0.000165	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKB1—psoriasis	7.55e-06	0.000159	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—psoriasis	6.85e-06	0.000145	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—psoriasis	6.81e-06	0.000144	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—psoriasis	6.78e-06	0.000143	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CAT—psoriasis	6.37e-06	0.000134	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—psoriasis	6.23e-06	0.000132	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—psoriasis	6.21e-06	0.000131	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—psoriasis	5.69e-06	0.00012	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—psoriasis	5.18e-06	0.000109	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOE—psoriasis	4.95e-06	0.000104	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—psoriasis	4.74e-06	0.0001	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—psoriasis	4.31e-06	9.1e-05	CbGpPWpGaD
